Study reveals nervous system's role in asthma attacks

July 22, 2014 by Marcia Malory, Medical Xpress report
Obstruction of the lumen of a bronchiole by mucoid exudate, goblet cell metaplasia, and epithelial basement membrane thickening in a person with asthma. Credit: Yale Rosen/Wikipedia/CC BY-SA 2.0

(Medical Xpress)—Asthma is a debilitating condition that kills 250,000 people around the world each year. People with asthma have hyperreactive airways and thickened lung walls obstructed with mucus. During an asthma attack, which could be fatal, airways constrict even further in the presence of a trigger, such as pollen, dust mites or a viral infection. Current asthma therapies treat asthma attacks as immune responses and focus on immune system suppression. However, a study by Dimitri Trankner of Howard Hughes Medical Institute in Virginia and his colleagues, published in the Proceedings of the National Academy of Sciences, shows that sensory neurons control bronchial hyperactivity.

Scientists know the plays an important role in asthma. However, treatments that suppress the immune response and relieve inflammation do not control completely. This indicates that asthma involves an additional mechanism.

Trankner and his team thought this mechanism might be nervous system activity. Sensory in the vagal ganglia moderate respiratory responses such as coughing, and earlier studies have shown that the nervous system modulates asthma symptoms.

To test their hypothesis, the researchers genetically engineered mice with different groups of inactive neurons. They gave the mice an allergy to ovalbumin, egg white protein. This allergy causes asthma-like symptoms: airway hyperreactivity and constriction of the airways.

When exposed to ovalbumin, all but one group of mice experienced these symptoms. In the asymptomatic mice, nerve cells that express a receptor called transient receptor potential vallinoid 1 (TRPV1) were inactive. While these mice did not exhibit asthma-like symptoms, their immune systems did respond to the allergen; they produced ovalbumin-specific immunoglobulins and accumulated leukocytes in their lungs.

Deactivating TRPV1-expressing neurons in the vagal ganglia, but not in other parts of the body, still resulted in the suppression of asthma symptoms.

When the researchers stimulated TRPV1-expressing neurons in mice allergic to ovalbumin, bronchoconstriction worsened, even when no ovalbumin was present. This response did not occur in mice without the allergy, suggesting that an allergy primes the immune system to send neuron-sensitizing signals; sensitized neurons then cause asthma symptoms when stimulated.

Trankner's team thought a chemical known as sphingosine-1-phosphate (S1PR3), found in the lungs of ovalbumin-sensitized mice and implicated in the development of asthma, might be involved in signaling. When they injected the mice with an S1PR3 agonist, all of the , except those that did not express TRPV1, experienced airway hyperactivity, even without ovalbumin exposure. This suggests that lung inflammation leads to the release of chemicals that sensitize , which then cause asthma attacks. The researchers think new therapies could target these neurons.

Explore further: Team shows how childhood viral infection leads to increased risk for allergic asthma as adult

More information: Population of sensory neurons essential for asthmatic hyperreactivity of inflamed airways, Dimitri Tränkner, PNAS, DOI: 10.1073/pnas.1411032111

Abstract
Asthma is a common debilitating inflammatory lung disease affecting over 200 million people worldwide. Here, we investigated neurogenic components involved in asthmatic-like attacks using the ovalbumin-sensitized murine model of the disease, and identified a specific population of neurons that are required for airway hyperreactivity. We show that ablating or genetically silencing these neurons abolished the hyperreactive broncho-constrictions, even in the presence of a fully developed lung inflammatory immune response. These neurons are found in the vagal ganglia and are characterized by the expression of the transient receptor potential vanilloid 1 (TRPV1) ion channel. However, the TRPV1 channel itself is not required for the asthmatic-like hyperreactive airway response. We also demonstrate that optogenetic stimulation of this population of TRP-expressing cells with channelrhodopsin dramatically exacerbates airway hyperreactivity of inflamed airways. Notably, these cells express the sphingosine-1-phosphate receptor 3 (S1PR3), and stimulation with a S1PR3 agonist efficiently induced broncho-constrictions, even in the absence of ovalbumin sensitization and inflammation. Our results show that the airway hyperreactivity phenotype can be physiologically dissociated from the immune component, and provide a platform for devising therapeutic approaches to asthma that target these pathways separately.

Related Stories

Team shows how childhood viral infection leads to increased risk for allergic asthma as adult

September 12, 2012
(Medical Xpress)—Researchers in the Division of Pulmonary, Allergy and Critical Care Medicine at the University of Pittsburgh School of Medicine have shown in an animal model that a common childhood virus disables the normal ...

Study reveals new link to asthma

August 23, 2012
(Medical Xpress)—Researchers at King's have established a significant link between asthma and an immune response called 'Th17', previously only attributed to inflammatory conditions such as multiple sclerosis.

No harm in yoga: But not much help for asthma sufferers

June 2, 2014
Yoga has long been promoted as a method for improving physical and mental well-being. And although yoga is often suggested to asthma sufferers to help alleviate symptoms, a new study found little evidence that yoga will improve ...

A treatment for obesity-associated asthma

December 16, 2013
(Medical Xpress)—Research conducted at Boston Children's Hospital indicates that obesity might cause asthma via factors in the immune system and suggests a new way of treating asthma in obese people—who often respond ...

Fungal infections can trigger and exacerbate asthma

September 2, 2013
(Medical Xpress)—A common fungal infection can trigger asthma and make it much worse by way of a route not targeted by existing asthma drugs, report researchers at Boston Children's Hospital. Their findings, published online ...

Researchers find potential target for drug to treat allergic asthma

March 5, 2014
An enzyme that helps maintain immune system function by "throwing away" a specific protein has a vital role in controlling symptoms of allergic asthma, new research in mice suggests.

Recommended for you

Chronic inflammation causes loss of muscle mass during aging

January 12, 2018
People start losing muscle mass at the age of 40—about some 10 percent of the total muscle mass for each 10-year period, which may lead to fall-related injuries, slowing metabolism and reduced quality of life. Today, very ...

Breathing exercises help asthma patients with quality of life

December 13, 2017
A study led by the University of Southampton has found that people who continue to get problems from their asthma, despite receiving standard treatment, experience an improved quality of life when they are taught breathing ...

Study highlights the need for research into prevention of inflammatory bowel disease

December 7, 2017
Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialised and westernised, a new study has found.

Air pollution can increase asthma risk in adults, even at low levels

November 24, 2017
Living close to a busy road can be bad for your respiratory health if you are middle aged, new Australian research has found.

Evidence found of oral bacteria contributing to bowel disorders

October 20, 2017
(Medical Xpress)—An international team of researchers has found evidence that suggests certain types of oral bacteria may cause or exacerbate bowel disorders. In their paper published in the journal Science, the group describes ...

New compound discovered in fight against inflammatory disease

September 22, 2017
A 10-year study by University of Manchester scientists for a new chemical compound that is able to block a key component in inflammatory illness has ended in success.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.